Is Revolution Medicines, Inc. profitable?

Revolution Medicines, Inc. is not currently profitable: it reported a net loss of $1.4B over the trailing twelve months, a -76423.3% net margin.

What is Revolution Medicines, Inc.'s earnings per share?

Revolution Medicines, Inc.'s diluted EPS over the trailing twelve months is $-7.10.

Where does Revolution Medicines, Inc.'s income statement data come from?

Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Revolution Medicines, Inc. RVMD Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$1.13B+65.4%	$987.33M+66.6%	$880.49M+59.2%	$769.73M+51.2%	$680.53M+44.1%
General and administrative	$261.28M+140%	$195.04M+102%	$156.57M+55.4%	$127.77M+38.4%	$108.9M+27.8%
Other operating expenses	$1.39B+75.7%	$1.18B+71.5%	$1.04B+58.6%	$897.5M+49.2%	$789.43M+41.6%
Total operating expenses	$1.39B+75.7%	$1.18B+71.5%	$1.04B+58.6%	$897.5M+49.2%	$789.43M+41.6%
Operating income	-$1.39B-75.7%	-$1.18B-71.5%	-$1.04B-58.8%	-$897.5M-49.4%	-$789.43M-42.8%
Interest expense	$36.43M—	$24.23M—	$12.3M—	$867K—	——
Interest income	$85.29M-3.1%	$90.69M+4.4%	$90.63M+7.1%	$88.96M+18.3%	$88.04M+37.2%
Other income (expense), net	$18.4M-79.8%	$54.33M-38.7%	$75.32M-12.9%	$84.68M+8.6%	$91.17M+40.1%
Income before income taxes	-$1.37B-96.4%	-$1.13B-88.3%	-$961.73M-69.7%	-$812.81M-55.5%	-$698.26M-43.1%
Net income	-$1.37B-96.7%	-$1.13B-88.5%	-$960.98M-69.5%	-$812.06M-56.4%	-$697.51M-44.0%
Diluted earnings per share	-$7.10-77.1%	-$5.94-65.9%	-$5.18-41.5%	-$4.51-21.6%	-$4.01-5.0%
Basic earnings per share	-$7.10-77.1%	-$5.94-65.9%	-$5.18-41.5%	-$4.51-21.6%	-$4.01-5.0%
Weighted-average shares, diluted	766M+11.4%	756.1M+13.8%	733.7M+20.3%	711.3M+28.8%	687.9M+39.2%
Weighted-average shares, basic	766M+11.4%	756.1M+13.8%	733.7M+20.3%	711.3M+28.8%	687.9M+39.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$1.37B-97.8%	-$1.13B-88.4%	-$961.67M-71.0%	-$808.9M-55.6%	-$694.6M-43.2%
Fair Value Adjustment Of Warrants	$33.59M—	$15.36M—	——	——	——
Net unrealized gains (losses) on securities still held	-$2.32M—	$1.92M—	——	——	——
Other income, net (Note 6)	——	——	——	——	——
EBITDA	-$1.38B-76.1%	-$1.17B-72.0%	-$1.03B-59.1%	-$890.67M-49.7%	-$782.71M-42.9%
EBIT	-$1.39B-75.7%	-$1.18B-71.5%	-$1.04B-58.8%	-$897.5M-49.4%	-$789.43M-42.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Revolution Medicines, Inc. profitable?: Revolution Medicines, Inc. is not currently profitable: it reported a net loss of $1.4B over the trailing twelve months, a -76423.3% net margin.
What is Revolution Medicines, Inc.'s earnings per share?: Revolution Medicines, Inc.'s diluted EPS over the trailing twelve months is $-7.10.
Where does Revolution Medicines, Inc.'s income statement data come from?: Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.